Find answers in short
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Here are the short answers to all 5 questions based on the clinical case (43-year-old premenopausal woman, ER/PR negative, HER2 negative — triple-negative breast cancer):
Important clarification from the case: The patient's ER, PR, and HER2 are all negative (triple-negative breast cancer). Hormonal therapy (tamoxifen, aromatase inhibitors) is NOT indicated in this patient because hormone receptor expression is absent. The questions below are answered as written in the exam (treating it as a hormone receptor-positive scenario for academic purposes), which is what the answer key also starts doing.
Q1. First-line adjuvant hormonal therapy for premenopausal women with hormone receptor-positive breast cancer?
Tamoxifen (20 mg/day orally for 5–10 years) is the 1st-line adjuvant hormonal therapy for premenopausal women with ER+ breast cancer.
— Goodman & Gilman's Pharmacological Basis of Therapeutics
Q2. Why is tamoxifen preferred in premenopausal patients?
Tamoxifen is a selective estrogen receptor modulator (SERM) — it competitively blocks estrogen receptors in breast tissue regardless of the source of estrogen (ovary, adrenal, peripheral fat). In premenopausal women, the ovaries are the dominant estrogen source and are still functioning. Aromatase inhibitors cannot suppress ovarian estrogen production, so they are ineffective as monotherapy in premenopausal women. Tamoxifen works independently of ovarian status.
— Goldman-Cecil Medicine; Goodman & Gilman's
Q3. Can aromatase inhibitors (AIs) be used here? Why / why not?
No — not as monotherapy. AIs (anastrozole, letrozole, exemestane) block peripheral conversion of androgens to estrogen but cannot suppress ovarian estrogen production, which is the major source in premenopausal women. Using AIs alone would leave a large estrogen pool unchecked, potentially making them ineffective or even causing a reflex rise in gonadotropins and ovarian estrogen.
Exception: AIs can be used in premenopausal women only when combined with ovarian function suppression (OFS) — e.g., GnRH agonist + AI — in higher-risk patients. This combination further reduces recurrence compared to tamoxifen alone.
— Current Surgical Therapy 14e; Goldman-Cecil Medicine
Q4. Major adverse effects of tamoxifen?
| Category | Effect |
|---|---|
| Vasomotor | Hot flashes, night sweats |
| Gynecological | Vaginal bleeding/discharge, vaginal atrophy, menstrual irregularities, pruritus vulvae |
| Serious (FDA Boxed Warning) | Endometrial cancer (2–3× increased risk, especially >2 years use) |
| Thrombotic | Venous thromboembolism (DVT/PE) |
| Ocular | Cataracts, retinal deposits, decreased visual acuity |
| Hepatic | Fatty liver disease (rarely significant) |
— Goodman & Gilman's Pharmacological Basis of Therapeutics
Q5. If the patient becomes postmenopausal later, which drug class is preferred?
Aromatase inhibitors (AIs) — e.g., anastrozole, letrozole, exemestane. In postmenopausal women, ovarian estrogen production ceases, so the predominant estrogen source is peripheral aromatization of androgens. AIs block this effectively and are superior to tamoxifen in postmenopausal women, with further reductions in recurrence risk.
— Goodman & Gilman's; Harrison's Principles of Internal Medicine 22E
This is a shared conversation. Sign in to Orris to start your own chat.